US 12,083,109 B2
Neurokinin antagonists and uses thereof
David J. Anderson, Altadena, CA (US); Moriel Zelikowsky, Pasadena, CA (US); and Andrea Choe, Los Angeles, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Sep. 30, 2022, as Appl. No. 17/937,067.
Application 17/937,067 is a continuation of application No. 16/178,460, filed on Nov. 1, 2018, granted, now 11,458,129.
Claims priority of provisional application 62/580,834, filed on Nov. 2, 2017.
Prior Publication US 2023/0128029 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4545 (2006.01); A61P 43/00 (2006.01); G01N 33/68 (2006.01)
CPC A61K 31/4545 (2013.01) [A61P 43/00 (2018.01); G01N 33/68 (2013.01)] 19 Claims
 
1. A method of inhibiting, ameliorating, reducing the severity of, or treating one or more symptoms caused by social isolation stress, the method comprising:
identifying a subject as suffering from social isolation stress and in need of inhibiting, ameliorating, reducing the severity of, or treating one or more symptoms caused by the social isolation stress; and
administering an effective amount of a neurokinin receptor antagonist to the subject, wherein the neurokinin receptor antagonist is a NK3R antagonist, to thereby inhibit, ameliorate, reduce the severity of, or treat the one or more symptoms caused by the social isolation stress.